Canadian Rheumatology Association updates information on ocular toxicity monitoring and provides reassurance on cardiac safety at usual rheumatologic therapeutic doses.
Urgent need for a tailored screening panel for patients with CRCI, as typical formal neurocognitive testing was developed for very different situations.
